Clicky

Revance Therapeutics, Inc.(RVNC)

Description: Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.


Keywords: Biopharmaceutical Drugs Pain Plastic Surgery Migraine Neuropathic Pain Headache Toxins Rhinitis Botulinum Toxin Therapeutic Applications Botulism Neurotoxins Migraine Headache Botulinum Toxin Products Hyperhidrosis

Home Page: www.revance.com

RVNC Technical Analysis

1222 Demonbreun Street
Nashville, TN 37203
United States
Phone: 615 724 7755


Officers

Name Title
Mr. Mark J. Foley CEO & Director
Mr. Dustin S. Sjuts Pres
Mr. Tobin C. Schilke CFO & Principal Accounting Officer
Mr. Aubrey Rankin Consultant
Jessica Serra Head of Investor Relations & ESG
Mr. Dwight Moxie Sr. VP, Gen. Counsel & Corp. Sec.
Ms. Jeanie D. Herbert Sr. Director of Investor Relations & Corp. Communications
Ms. Taryn Conway VP of Marketing
Mr. Justin Ford Sr. VP of HR & Head of People
Ms. Azita Nejad Sr. VP of Technical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 12.3032
Price-to-Sales TTM: 16.289
IPO Date: 2014-02-06
Fiscal Year End: December
Full Time Employees: 495
Back to stocks